APR Nov/Dec 2022 - 51

« BIOPHARMACEUTICALS
Manufacturers and other companies developing these therapies will
play an instrumental role in working closely with the complex network
of industry stakeholders to advance these therapies and ensure they
are reaching those in need, which is the most progressive approach
for clinical development and patient care. It is anticipated that these
therapies will effectively address the struggles of millions of people
and their families in the journey towards better health.
References
1.
2.
8.
9.
10.
11.
12.
National Organization for Rare Diseases; Rare Disease Day: Frequently Asked Questions,
2022; Available at https://rarediseases.org/wp-content/uploads/2019/01/RDD-FAQ-2019.
pdf; Accessed September 27, 2022.
International Federation of Pharmaceutical Manufacturers and Associations; Tackling
Global Health Challenges: Rare Diseases; Available at https://www.ifpma.org/subtopics/
rare-diseases/#:~:text=It%20is%20estimated%20that%20one,to%20400%20
million%20people%20worldwide; Accessed September 27, 2022.
3.
4.
The Global Genes Project. RARE Diseases: Facts and Statistics. Available at Accessed
September 28, 2022. https://globalgenes.org/rare-disease-facts/
U.S. Department of Health and Human Services Food and Drug Administration Center
for Biologics Evaluation and Research. Long Term Follow-Up After Administration of
Human Gene Therapy Products, Guidance for Industry. Available at https://www.fda.gov/
media/113768/downloadJanuary 2020. Accessed September 27, 2022.
5.
American Society for Gene and Cell Therapy. Gene and Cell Therapy FAQs. Available at https://
asgct.org/education/more-resources/gene-and-cell-therapy-faqs#:~:text=In%20
vivo%20gene%20therapy%20means,returned%20to%20the%20patient's%20body.
Accessed September 27, 2022.
6.
7.
Association for the Advancement of Blood and Biotherapies. Facts About Cellular Therapies.
Available at https://www.aabb.org/news-resources/resources/cellular-therapies/factsabout-cellular-therapies.
Accessed September 27, 2022.
Food & Drug Administration; Approved Cellular and Gene Therapy Products. Available at
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approvedcellular-and-gene-therapy-products.
Accessed September 27, 2022.
13.
14.
Food & Drug Administration; What is Gene Therapy? Available at https://www.fda.gov/
vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy. Accessed
September 27, 2022.
Fierce Pharma. A $3million dollar gene therapy. Available at https://www.fiercepharma.
com/pharma/3m-gene-therapy-bluebird-breaks-own-record-fda-approval-skysona.
Accessed September 27, 2022.
CGT Live. Gene Therapy for Diabetic Macular Edema Halted Following Serious Adverse
Reaction. Available at https://www.cgtlive.com/view/gene-therapy-diabetic-macularedema-halted-following-serious-adverse-reaction
Accessed September 27, 2022.
CGT Live. Addressing Adverse Events in Gene Therapy. Available at https://www.cgtlive.
com/view/addressing-adverse-events-in-gene-therapy. Accessed September 27, 2022.
Food & Drug Administration. Long Term Follow-Up After Administration of Human Gene
Therapy Products. Available at https://www.fda.gov/media/113768/download. Accessed
September 27, 2022.
Carrier, A. L. Risk-Benefit Analysis of the use of Viral Vectors in Gene Therapy. Available at
https://www.emich.edu/chhs/health-sciences/programs/clinical-research-administration/
documents/theses/viral-vectors-in-gene-therapy.pdf. Accessed September 27, 2022.
McKinsey & Company. How Could Gene Therapy Change Healthcare in the Next 10 years?
Available at https://www.mckinsey.com/industries/life-sciences/our-insights/howcould-gene-therapy-change-healthcare-in-the-next-ten-years
About
the Author
Andy
Szczotka is the Chief Pharmacy Officer for
AscellaHealth. In this capacity, he is responsible for the
development, oversight and operation of clinical specialty
and medical drug services for clients, including self-insured
employer groups, TPAs, PBMs, Medicare and consumer-oriented markets. He
provides development for programs and services to support drug formulary
services, utilization management programs, national P&T Committees
and cost management programs while enhancing patient outcomes.
Andy supports new business development and new client acquisitions and
implementation, including expansion into new service offerings
www.americanpharmaceuticalreview.com |
| 51
»

http://www.americanpharmaceuticalreview.com

APR Nov/Dec 2022

Table of Contents for the Digital Edition of APR Nov/Dec 2022